Drug Approval | January 08, 2026
GSK’s Exdensur wins Japanese nod for severe asthma
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Subscribe To Our Newsletter & Stay Updated
